Status:
COMPLETED
TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis
Lead Sponsor:
University of Regensburg
Collaborating Sponsors:
University of Dublin, Trinity College
Universität Tübingen
Conditions:
Tinnitus
Eligibility:
All Genders
18-70 years
Brief Summary
Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Althou...
Detailed Description
The tinnitus detect (TIDE) consortium has been designed to identify and validate a biomarker for the presence and intensity of tinnitus. For this purpose, two test paradigms are combined which are der...
Eligibility Criteria
Inclusion
- (1) for tinnitus cases: a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
- (2) for controls: never experienced tinnitus
- (3) age 18 -70;
- (4) ability to understand and consent to the research;
- (5) ability to participate (hearing ability);
- (6) MoCa Test ≥ 26;
- (7) hyperacusis questionnaire score \< 27;
- (8) Hospital Anxiety and Depression Scale (HADS) \<14;
Exclusion
- (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint;
- (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing;
- (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis);
- (4) Meniere's disease or similar syndromes;
- (5) vestibular migraine;
- (6) serious internal, neurological or psychiatric conditions;
- (7) epilepsy or other CNS disorders (brain tumor, encephalitis);
- (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start;
- (9) change in anti-depressants/drugs ≤ 2 weeks
- (10) missing written informed consent
- (11) severe hearing loss - inability to communicate properly in the course of the study;
- (12) one deaf ear;
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2025
Estimated Enrollment :
560 Patients enrolled
Trial Details
Trial ID
NCT06520865
Start Date
August 1 2024
End Date
November 30 2025
Last Update
December 22 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois
Champaign, Illinois, United States, 61820
2
University of Texas
Austin, Texas, United States, 78712
3
Brai3n - Research center for Advanced, International, Innovative and Interdisciplinary Neuromodulation
Ghent, Belgium, 9000
4
University of Tuebingen
Tübingen, Baden-Wurttemberg, Germany, 72074